Our Science
Our Approach
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Scientific Insights
Publications
Pipeline & Programs
Pipeline
VE202
VE303
VE707
Commitment to Patients
Our Focus
How It Works
Disease Areas
Inflammatory Bowel Disease
C. difficile
Infection
Clinical Trials
Trials
COLLECTiVE202
RESTORATiVE303
Expanded Access Policy
Who We Are
Company
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Careers
Open Positions
Working at Vedanta
News
Press Releases
Our Science
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Publications
Pipeline & Programs
Pipeline
VE202
VE303
VE707
Commitment to Patients
How It Works
Inflammatory Bowel Disease
C. difficile
Infection
Trials
COLLECTiVE202
RESTORATiVE303
Expanded Access Policy
Who We Are
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Open Positions
Working at Vedanta
News
Press Releases
Press Releases
Year
All
2024
2023
2022
May 24, 2022
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
April 13, 2022
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
Pages:
1
2
3
Load More
Sorry, nothing found in this query
